UPDATE 1-Sanofi says U.S. watchdog to review Lemtrada resubmission

May 30, 2014 7:18 AM

13
0

PARIS May 30 (Reuters) - French drug company Sanofi said on Friday the U.S. Food and Drug Administration (FDA) had agreed to review its U.S. unit Genzyme's resubmission of its application for its Lemtrada drug for the treatment of relapsing forms of multiple sclerosis.

A six-month review period has been assigned for the Lemtrada resubmission and Genzyme expects an FDA action in the fourth quarter, Sanofi said in a statement.